Ponesimod-d_4

Cat. No.:	HY-10569S
Molecular Formula:	$C_{23}H_{21}D_4ClN_2O_4S$
Molecular Weight:	465
Target:	Isotope-Labeled Compounds; LPL Receptor
Pathway:	Others; GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Ponesimod-d_4 (ACT-128800-d_4)is the deuterium labeledPonesimod(HY-10569)[1]. Ponesimod (ACT-128800) is a potent, selective and orally active agonist of $S1P_1$, with an IC_{50} of 6 nM in a radioligand binding assay. Ponesimod activates $S1P_1$-mediated signal transduction with high potency (EC_{50}=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation[2][3][4].
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA